{
  "sections": {
      "allergyimmunology": {
          "path": "penflip\/allergyimmunology",
          "title": "Allergy\/Immunology",
          "cards": [
              {
                  "slug": "anaphylaxis",
                  "title": "Anaphylaxis\n"
              },
              {
                  "slug": "angioedema",
                  "title": "Angioedema\n"
              }
          ]
      },
      "cardiovascular": {
          "path": "penflip\/cardiovascular",
          "title": "Cardiovascular",
          "cards": [
              {
                  "slug": "acls-2015-guidelines-for-cardiac-arrest",
                  "title": "ACLS 2015 Guidelines for Cardiac Arrest\n"
              },
              {
                  "slug": "acute-limb-ischemia",
                  "title": "Acute Limb Ischemia\n"
              },
              {
                  "slug": "afib-anticoagulation",
                  "title": "Anticoagulation in Atrial Fibrillation\n"
              },
              {
                  "slug": "aortic-dissection-description",
                  "title": "Aortic Dissection Description\n"
              },
              {
                  "slug": "brugada",
                  "title": "Brugada Syndrome\n"
              }
          ]
      },
      "contributor-guide": {
          "path": "penflip\/contributor-guide",
          "title": "Contributor Guide",
          "cards": [
              {
                  "slug": "anatomy-of-a-pv-card",
                  "title": "Anatomy of a PV Card\n"
              },
              {
                  "slug": "authors-guide",
                  "title": "Introduction\n"
              },
              {
                  "slug": "jabberwocky",
                  "title": "Jabberwocky\n"
              }
          ]
      },
      "critical-care": {
          "path": "penflip\/critical-care",
          "title": "Critical Care",
          "cards": [
              {
                  "slug": "abg-interpretation",
                  "title": "Arterial Blood Gas Interpretation\n"
              }
          ]
      },
      "dermatology": {
          "path": "penflip\/dermatology",
          "title": "Dermatology",
          "cards": [
              {
                  "slug": "rashes-an-approach-to-the-unknown-rash",
                  "title": "Rashes: An approach to the unknown rash\n"
              }
          ]
      },
      "ent": {
          "path": "penflip\/ent",
          "title": "ENT",
          "cards": [
              {
                  "slug": "dental-infections",
                  "title": "Dental Infections\n"
              }
          ]
      },
      "general-surgery": {
          "path": "penflip\/general-surgery",
          "title": "General Surgery",
          "cards": [
              {
                  "slug": "abdominal-pain-diagnostics",
                  "title": "Diagnostic Studies for Acute Abdominal Pain\n"
              }
          ]
      },
      "infectious-disease": {
          "path": "penflip\/infectious-disease",
          "title": "Infectious Disease",
          "cards": [
              {
                  "slug": "infectious-diseases",
                  "title": "ost-Exposure Prophylaxis (PEP): Non-Occupational Contact\n"
              },
              {
                  "slug": "strep-pharyngitis",
                  "title": "Streptococcal Pharyngitis\n"
              }
          ]
      },
      "neurology": {
          "path": "penflip\/neurology",
          "title": "Neurology",
          "cards": [
              {
                  "slug": "keeping-cards-updated",
                  "title": "Stroke: Contraindications for Thrombolytics\n"
              },
              {
                  "slug": "vertigo",
                  "title": "Acute Vestibular Syndrome vs Stroke\n"
              }
          ]
      },
      "orthopedics": {
          "path": "penflip\/orthopedics",
          "title": "Orthopedics",
          "cards": [
              {
                  "slug": "orthopedics",
                  "title": "C1 and C2 Fractures\n"
              }
          ]
      },
      "pharmacology": {
          "path": "penflip\/pharmacology",
          "title": "Pharmacology",
          "cards": [
              {
                  "slug": "pain-medications",
                  "title": "Initial ED Pain Medication Options in Adults\n"
              }
          ]
      },
      "toxicologymedications": {
          "path": "penflip\/toxicologymedications",
          "title": "Toxicology\/Medications",
          "cards": []
      }
  },
  "cards": {
      "anaphylaxis": {
          "slug": "anaphylaxis",
          "title": "Anaphylaxis\n",
          "path": "penflip\/allergyimmunology\/anaphylaxis.txt",
          "markdown": "# Anaphylaxis\n\n**Definition:** a serious allergic reaction that is rapid in onset and might cause death\n**Mechanism:** IgE-mediated immune reaction\n**Pearl:** Hypotension is NOT required to diagnose anaphylaxis\n**Triggers:** Almost any food, allergens, or medication can be a trigger\n- common culprits: antibiotics (esp. beta-lactams), NSAIDs, peanuts, shellfish\n**Organ Involvement:** Skin 80-90%, Resp. 70%, GI 45%, CV 45%, CNS 15%\n**Biphasic anaphylaxis pattern:** 2nd flare may occur despite trigger removed (typically within 72 hours of onset)\n\n### Diagnostic Criteria\n> Highly likely if 1 of 3 criteria fulfilled per 2nd National Institute of Allergy and ID\/Food Allergy and Anaphylaxis Network\n\n1. Acute onst (minutes - several hours) with invovlement of skin, mucosa, or both (e.g. hives, pruritis, flushing, facial angio edema) AND at least 1 of following:\n\t- Respiratory compromise (e.g. shortness of breath, wheezing, stridor, reduced PEF, hypoxemia)\n\t- Reduced BP or associate symptoms of end-organ dysfunction (e.g. hypotonia, syncope, incontinence)\n    \n2. Two or more of following that occur rapidly after exposure to likely allergen\n\t- Involvement of skin-mucosal tissue\n    - Respiratory compromise\n    - Reduced BP or associated dx\n    - Persistent GI symptoms\n    \n3. Reduced BP after exposure to known allergen\n\t- Infants\/children: Low SBP (age specific) or > 30% decrease in SBP\n    - Adults: SBP < 90 mmHg or > 30% decrease in person's baseline\n    \n> *Low Pediatric SBP Definitions*\n> Age 1mo - 1yr:\tSBP < 70 mmHg\n> Age 1yr - 10yrs: \tSBP < (70 mmHg + age*2)\n\n### ED Management\n1. Supine position, ABCs\n2. <span class=\"drug\">IM epinepherine<\/span> STAT. Repeat every 5-15min if refractory\n\t- 0.3 - 0.5mg for adults = 0.3-0.5 mL of 1:1000 concentration of epinepherine\n    - 0.15 mg of pt wt < 30kg\n    - **IM injection into lateral thigh** -- quickest absorption centrally\n3. IV fluids: 2 liters\n4. <span class=\"drug\">H1 antagonist<\/span> e.g. diphenhydramine\n5. <span class=\"drug\">H3 antagonist<\/span> e.g. ranitidine\n6. <span class=\"drug\">Glucocorticods<\/span> e.g. methylprednisone, may blunt biphasic reaction\n7. <span class=\"drug\">Beta-agonist nebulizer<\/span> e.g. albuterol, for wheezing\n8. Consider <span class=\"drug\">Glucagon<\/span> 3.5-5 mg IV if refractory to epinepherine and on beta-blockers\n9. If discharging patient home after observation, prescribe <span class=\"drug\">EpiPen<\/span>!\n\n---\n\n## References\n- Simons FER. *J Allergy Clin Immunol* 2010;125:S161-81. \n- Arnold JJ, Williams PM. *Amer Fam Phys* 2011; 84(10):1111-8.\n"
      },
      "angioedema": {
          "slug": "angioedema",
          "title": "Angioedema\n",
          "path": "penflip\/allergyimmunology\/angioedema.txt",
          "markdown": "# Angioedema\n\n**Definition:** self-limited, asymmetric, localized, non-pitting swelling\n\n**Background**\n\n- 15% of population; 50% present with urticaria\n- Common sites: periorbital, lips, tongue, extremity, bowel wall\n- Main cause of death = laryngeal edema (25-40% mortality if present)\n\n**Syndromes**\n\n1. Idiopathic Angioedema\n\n\t- 38% of patients\n    \n2. Allergic or IgE Mediated Angioedema\n\n\t- Type I hypersensitivity reaction\n\t- Commonly from food or medications\n\t- Tx: allergen avoidance, antihistamine, H2 blockers, glucocorticoid, epinephrine for laryngeal edema\n    \n3. Hereditary Angioedema\n\n\t- C1 esterase inhibitor deficiency\n    - Triggers include: trauma (especially dental trauma), anxiety, menstruation, infection, exercise, alcohol consumption, and stress\n\t- Prophylaxis tx = <span class=\"drug\">danazol<\/span> better than <span class=\"drug\">tranexamic acid<\/span> and <span class=\"drug\">aminocaproic acid<\/span>\n\t- Acute tx = <span class=\"drug\">FFP<\/span> (or C1 inhibitor concentrate - given in Europe\/Canada only), usual IgE-mediated treatment regimen ineffective except epinephrine for laryngeal edema\n    \n4. ACE Inhibitor Angioedema\n\n\t- Up to 2.2% of those taking <span class=\"drug\">ACE-I<\/span>\u2019s\n\t- From elevated levels of bradykinin\n\t- Highest incidence during 1st month of starting medication, but can occur years after\n\t- 5x more common in African-Americans compared to Caucasians\n\t- Controversial whether patient can take <span class=\"drug\">ARB<\/span>s (doesn\u2019t cause elevated bradykinin) as well \u2013 some with angioedema.\n\t- Tx = discontinue med, usual IgE-mediated treatment regimen ineffective except epinephrine for laryngeal edema\n\n**Treatment philosophy: **Low threshold to protect airway by intubation\n**Pearl: ** Be sure to prescribe patients <span class=\"drug\">Epi-pen<\/span>\n\n---\n\n### Admission Guidelines for Angioedema\n*Ishoo E et al. Otolaryngol Head Neck Surg 1999; 121:263-8.*\n\n- Retrospective study of 93 episodes in 80 patients (1985-95) with no deaths \n- 9.7% cases required intubation\/tracheostomy\n\n**Causes:** 39% from ACE-I (generally more severe than allergic angioedema) \n**Disposition:** 25% outpt, 23% floor, 53% ICU\n**ICU admissions** correlated with voice change, hoarseness, dyspnea, rash Airway intervention correlated with voice change, hoarseness, dyspnea, stridor\n\n**Proposed staging system:**\n\n- Stage I: Facial rash, facial edema, lip edema - outpatient\n- Stage II: Soft palate edema \u2013 outpatient or floor\n- Stage III: Lingual edema --> ICU (7% of stage III pts got airway intervention) \n- Stage IV: Laryngeal edema \u2013> ICU (24% of stage IV pts got airway intervention)\n\n---\n\n## References\n\n- Temino VM, Peebles RS. Am J Med 2008; 121: 282-6 and Emedicine.com.\n- Ishoo E et al. Otolaryngol Head Neck Surg 1999; 121:263-8.\n\n\n\n\n"
      },
      "acls-2015-guidelines-for-cardiac-arrest": {
          "slug": "acls-2015-guidelines-for-cardiac-arrest",
          "title": "ACLS 2015 Guidelines for Cardiac Arrest\n",
          "path": "penflip\/cardiovascular\/acls-2015-guidelines-for-cardiac-arrest.txt",
          "markdown": "# ACLS 2015 Guidelines for Cardiac Arrest\n\n![acls-2015-ca-algorithm.png](images\/acls-2015-ca-algorithm.png)\n\n##CPR\n- ETCO2 < 10 mm Hg, attempt to improve CPR quality\n- If no advanced airway, 30:2 compression-ventilation ratio\n- If advanced airway inplace, continuous compressions and 1 breath every 6 seconds.\n\n##Drug Therapy\n- <span class=\"drug\">Epinephrine<\/span> IV\/IO dose: 1 mg every 3-5 minutes\n- <span class=\"drug\">Amiodarone<\/span> IV\/IO dose: 1st - 300 mg bolus, 2ng - 150 mg bolus\n\n##Advanced Airway\n- Endotracheal intubation or subraglottic airway\n\n## Return of Spontaneous Circulation (ROSC)\n- Pusle and blood pressure\n- Abrupt sustained increase in ETCO2 (typically >\/= 40 mm Hg)\n\n## Recersible Causes\n- **H**ypovolemia\n- **H**ypoxia\n- **H**ydrogen ion (acidosis)\n- **H**ypo\/hyper-kalemia\n- **H**ypothermia\n- **T**ension pneuomthorax\n- **T**amponade, cardiac\n- **T**oxins\n- **T**hrombosis, pulmonary\/coronary\n\n## Indications of considering stopping CPR\n- ETCO2 < 10 mm Hg after 20 minutes (*Intubated patients*)\n\n\n##References:\nLink MS, et al. Part 7: Adult Cardiovascular Life Support: 2015 American Heart Association Guidelines Update for Cardiopulmonary Resusitation and Emergency Cardiovascular Care. * Circulation*. 2015 Nov 3; 132(18 Suppl 2):S444-64.\n\n"
      },
      "acute-limb-ischemia": {
          "slug": "acute-limb-ischemia",
          "title": "Acute Limb Ischemia\n",
          "path": "penflip\/cardiovascular\/acute-limb-ischemia.txt",
          "markdown": "# Acute Limb Ischemia\n\n**_True vascular emergency_**\n\n**Golden Window** = 6 hours (before irreversible neuromuscular damage) \n**Etiologies:** typically thromboembolic cause\n**Less common causes:** Vascular dissection, compartment syndrome, thoracic outlet syndrome, trauma, vasospasm, vasculitis, low intravascular volume\n\n**Focused physical exam**\n1. **Cardiac** \u2013 check for murmur, atrial fibrillation\n2. **Extremity** \u2013 check for signs of chronic peripheral vascular dz (foot\nulcer, decrease arterial pulse in contralateral extremity,\nhair loss, muscle atrophy)\n3. **Neurological** \u2013 check for sensory and motor loss\n4. **Ankle-brachial index measurement**\n\n- ABI = (highest of DP or PT pressure on that side) \/ (highest of left or right brachial artery pressure)\n    \n5. **Vascular** \u2013 grade peripheral pulses\n\n|Grade|Finding|\n|---------|-----------|\n| 0 | No Doppler signal |\n| 1 | Reduced pulse |\n| 2 | Normal |\n| 3 | Increased pulse |\n| 4 | Bounding pulse |\n    \n ### Rutherford Classification scheme for ALI\n \n- Thrombotic occlusions usually class I or IIA because of presence of collateral vasculature\n- Embolic occlusions usually class IIB or III\n\n **Class I**\n - Category: Viable\n - Prognosis: No immediate limb threat\n - Sensory Loss: None\n - Muscle Weakness: None\n - Arterial Doppler: Audible\n - Venous Doppler: Audible\n \n **Class IIA**\n - Category: Threatened, marginal\n - Prognosis: Salvagable if treated promptly\n - Sensory Loss: Minimal, none\n - Muscle Weakness: None\n - Arterial Doppler: +\/- Audible\n - Venous Doppler: Audible\n \n ** Class IIB**\n - Category: Threatened, immediate\n - Prognosis: Salvagable if treated immediately\n - Sensory Loss: More than just toes\n - Muscle Weakness: Mild to moderate\n - Arterial Doppler: Rare audible\n - Venous Doppler: Audible\n \n ** Class III**\n - Category: Irreversible\n - Prognosis: Limb loss or permanent damage\n - Sensory Loss: Profound\n - Muscle Weakness: Profound\n - Arterial Doppler: None\n - Venous Doppler: None\n \n\n### ED Tests\n- ABI, EKG\n- CBC, Type and screen, Basic metabolic panel, PT\/PTT,\nCreatine kinase (CK), Troponin\n- First line imaging = Digital subtraction angiography (DSA)\n- U\/S, CTA, MRA \u2013 not well studied in ALI and loss of time-to-\nintervention\n- No imaging if unstable patient --> go straight to amputation\n\n### ED Treatment\n- ASA\n- Unfractionated heparin (consider no bolus and lower infusion\nb\/c risk of hemorrhage)\n- Position extremity in dependent position\n- Avoid extremes of temperature\n- Pain control\n\n### Management Plan\n\t\n    - Interventional radiology = Catheter-directed (intra-arterial)\nthrombolysis +\/-Mechanical thrombectomy: If Class I or IIA ischemia; duration <14 days, esp if bypass graft; high operative risk\n\n\t- Operating room for open thrombectomy, bypass: If Class IIB or III ischemia; symptoms > 14 days\n\n\t- Amputation: If class III and high risk for reperfusion injury\n\n## References\n\n1. Rutherford et al. J Vasc Surg. 1997; 26:517-38.\n"
      },
      "afib-anticoagulation": {
          "slug": "afib-anticoagulation",
          "title": "Anticoagulation in Atrial Fibrillation\n",
          "path": "penflip\/cardiovascular\/afib-anticoagulation.txt",
          "markdown": "# Anticoagulation in Atrial Fibrillation\n\nAtrial Fibrillation (AF) = 5x risk for CVA and increases with age \n\n**Stroke risk stratification for patients with AF:**\n\n- Prior CVA or TIA\n- HTN\n- Age\u226575\n- CHF\n- Poor LV function\n- DM\n\n**CHADS2 stroke risk score:**\n\n- C = Congestive heart failure (1 pt)\n- H = Hypertension (1 pt)\n- A=Age\u226575(1pt)\n- D=DM(1pt)\n- S2 = prior Stroke or TIA (2 pts)\n\n![chads2.jpg](images\/chads2.jpg)\n\n### Antithrombotic therapy based on risk factors\n\n- If age < 60 years and zero risk factors: No anticoagulation b\/c low risk for CVA\n- Anticoagulation goal with <span class=\"drug\">warfarin<\/span> is INR 2-3\n\n**Weak Risk Factors**\nTreat with <span class=\"drug\">aspirin<\/span> or <span class=\"drug\">warfarin<\/span>\n\n- Female gender \n- Age 65-74 \n- Coronary artery disease \n- Thyrotoxicosis\n\n**Moderate Risk Factors**\nTreat with <span class=\"drug\">aspirin<\/span> or <span class=\"drug\">warfarin<\/span> (1 risk factor) or <span class=\"drug\">warfarin<\/span> (>1 risk factor)\n\n- Age > 75 \n- hypertension\n- Heart failure LVEF \u2264 35% \n- Diabetes mellitus\n\n**High Risk Factors**\nTreat with <span class=\"drug\">warfarin<\/span>\n\n- Prior CVA, TIA, embolism \n- Mitral stenosis \n- Mechanical heart valve\n\n---\n\n## References\n- Waldo AL. Cardiol Clin 2009; 27:125-35.\n- Gage BF et al. JAMA 2001;285:2864\u201370.\n- AHA\/ ACC\/ European Soc of Cardiology 2006 revised guidelines for antithrombotic therapy based on stroke risk\n\n"
      },
      "aortic-dissection-description": {
          "slug": "aortic-dissection-description",
          "title": "Aortic Dissection Description\n",
          "path": "penflip\/cardiovascular\/aortic-dissection-description.txt",
          "markdown": "# Aortic Dissection Description\n\nWrite here...\n"
      },
      "brugada": {
          "slug": "brugada",
          "title": "Brugada Syndrome\n",
          "path": "penflip\/cardiovascular\/brugada.txt",
          "markdown": "# Brugada Syndrome\n\n- Genetically linked, cardiac sodium channelopathy\n- High risk for sudden death in young, healthy adults because VTach\/VFib\n- Mean age of sudden death = 41 \u00b1 15 years\n- Higher prevalence in males and Asian descent\n- Atrial fibrillation associated in 10-20% cases\n\n### EKG Findings\n\n- 3 types\n- Type 1 most specific for Brugada, *highest risk for syncope and sudden death*\n\n![brugada.png](images\/brugada.png)\n\n### Differential Diagnosis\n\n- After electrical cardioversion Arrhythmogenic RV dysplasia\n- Atypical right BBB\n- Acute MI, esp RV infarct\n- Acute myopericarditis\n- Compression of RV outflow tract Disorders of central\/auton nerv systems \n- Dissecting aortic aneurysm\n- Duchenne muscular dystrophy\n- Friedreich ataxia\n- Early repolarization, especially in athletes Hypothermia\n- Pericardial effusion\n- Pulmonary embolism\n- Left ventricular hypertrophy\n- Mediastinal tumor\n- Pectus excavatum\n\n### Treatment\nTreatment: Implantable cardiac defibrillator for Brugada Type 1 PLUS:\n\n- Aborted sudden cardiac death\n- Syncope, seizure, or noctural agonal respirations without alternative cause\n- Family hx of sudden cardiac death (likely from Brugada) AND positive EPS study\n- A positive EPS study\n\nOtherwise: close followup with cardiologist\n\n---\n\n## References\n- Antzelevitch C et al. Brugada Syndrome: Report of the Second Consensus Conference. Circulation. 2005; 111:659-670.\n\n\n\n\n\n"
      },
      "anatomy-of-a-pv-card": {
          "slug": "anatomy-of-a-pv-card",
          "title": "Anatomy of a PV Card\n",
          "path": "penflip\/contributor-guide\/anatomy-of-a-pv-card.txt",
          "markdown": "# Anatomy of a PV Card\n\nThis guide will show you the pieces of an original PV Card and how to edit them as plain text, using  [Markdown.][markdown] All this formating can be done as plain text, i.e. you can literally type \"### Section Heading\" or you can use the formating tools at the top of the screen to do the formating for you, much like using Microsoft Word.\n\nUsing [Markdown][markdown] may seem like an unnecessary step, but this helps us convert the cards to HTML, which is the most portable format for digital content distribution. Using that HTML we can make a website, mobile app, or even an e-book. All from the same document! That power is what we're going for.\n\nYou can see the [original Anaphylaxis card](https:\/\/www.google.com\/url?q=https:\/\/dl.dropboxusercontent.com\/u\/5247611\/Anaphylaxis.pdf&usd=2&usg=ALhdy29c2fo3KNeoYa4PJaXj-bVONzhxZQ) and compare it to the [Markdown version of the card][anaphylaxis].\n\n- [Card Title](#card-title)\n- [Section Titles](#section-title)\n- [Emphasis](#emphasis)\n- [Pull Quote](#pull-quote)\n- [Lists](#lists)\n- [Drug Names](#drug-names)\n- [References](#references)\n\n---\n\n<a name=\"card-title\"><\/a>\n## Card Title\nAll cards begin with their title. In the original cards it looks like this:\n![title.png](images\/title.png)\n\nIn [Markdown][markdown] it is an H1 header and looks like this:\n```no-highlight\n# Anaphylaxis\n```\n\nYou can see in the original cards that the [references](#references) were at the top. We are moving these to the more traditional spot at the end of the card. \n\n---\n\n<a name=\"section-title\"><\/a>\n## Section Titles\nWithin the card section titles separate the main content areas.\n![sections.png](images\/sections.png)\n\nIn [Markdown][markdown] it is an H3 header and looks like this:\n```no-highlight\n### ED Management\n```\n---\n\n<a name=\"emphasis\"><\/a>\n## Emphasis\n**Bold** text is the most common emphasis in the PV Cards. There are occassional *italics.*\n\nHere is some **bold** text from the [Anaphylaxis][anaphylaxis] card:\n![bold.png](images\/bold.png)\n\nIn [Markdown][markdown] it is simple:\n```no-highlight\n**Definition:** a serious allergic reaction that is rapid in onset and might cause death\n**Mechanism:** IgE-mediated immune reaction\n**Pearl:** Hypotension is NOT required to diagnose anaphylaxis\n**Triggers:** Almost any food, allergens, or medication can be a trigger\n```\n\n*Italics* are just as simple:\n```no-highlight\n*This is all in italics.*\n```\n---\n\n<a name=\"pull-quote\"><\/a>\n## Pull Quote\nOccassionally you will want to emphasize more than a word or two, maybe a key pearl or definition. This is done by using a pull quote.\n\nHere is an example of some content that was included in a section header, but probably fits better as a pull quote:\n![quote.png](images\/quote.png)\n\nIn [Markdown][markdown] it is a paragraph of its own, must begin with \">\" and looks like this:\n```no-highlight\n> Highly likely if 1 of 3 criteria fulfilled per 2nd National Institute of Allergy and ID\/Food Allergy and Anaphylaxis Network\n```\n\nIf you want to use multiple lines, make sure there is only a single line break between them and begin each line with \">\". This pull quote even uses *italics* for emphasis within it!\n```no-highlight\n> *Low Pediatric SBP Definitions*\n> Age 1mo - 1yr:\tSBP < 70 mmHg\n> Age 1yr - 10yrs: \tSBP < (70 mmHg + age*2)\n```\n\n---\n\n<a name=\"lists\"><\/a>\n## Lists\nLists are a common feature of PV Cards. They can be ordered lists (1, 2, 3) or unordered lists (bullets), or a combination of both:\n![lists.png](images\/lists.png)\n\nAn unordered list is any list of items, each on their own new line, beginning with \"-\".\n```no-highlight\n- hepatitis\n- cholelithiasis\n- cholangitis\n- pancreatitis\n```\n- hepatitis\n- cholelithiasis\n- cholangitis\n- pancreatitis\n\nAn ordered list must begin each line with a number:\n```no-highlight\n1. pneumonia\n2. pneumothorax\n3. pulmonary embolism\n```\n1. pneumonia\n2. pneumothorax\n3. pulmonary embolism\n\nA sublist must begin with two spaces or a tab, it can be ordered or unordered:\n```no-highlight\n- Swollen Knee Differential\n\t- gout\n    - traumatic hemarthrosis\n    - septic joint\n- Red Eye Differential\n\t1. acute angle closure glaucoma\n    2. scleritis\n    3. dry eye\n    4. conjunctivits\n```\n- Swollen Knee Differential\n\t- gout\n    - traumatic hemarthrosis\n    - septic joint\n- Red Eye Differential\n\t1. acute angle closure glaucoma\n    2. scleritis\n    3. dry eye\n    4. conjunctivits\n    \n---\n\n<a name=\"drug-names\"><\/a>\n## Drug Names\nDrug names or other therapies get special treatment in PV Cards:\n![lists-drugs.png](images\/lists-drugs.png)\n\nUnfortunately there is no easy way to accomplish this in [Markdown](markdown). But, Markdown is turned into HTML. Don't be scared, but with a little HTML we can get just what we need:\n```no-highlight\n<span class=\"drug\">IM epinepherine<\/span> STAT. Repeat every 5-15min if refractory\n```\n---\n\n<a name=\"references\"><\/a>\n## References\nIn the original cards, references were at the top, with the [card title](#card-title):\n\n![title.png](images\/title.png)\n\nIn our version, we are putting the references in their own section at the end. The section is set off from the main card with a horizontal line. The title is an H2 header, followed by an ordered [list](#lists):\n ```no-highlight\n \n ---\n \n ## References\n- Simons FER. *J Allergy Clin Immunol* 2010;125:S161-81. \n- Arnold JJ, Williams PM. *Amer Fam Phys* 2011; 84(10):1111-8.\n```\n\n\n[markdown]: https:\/\/www.penflip.com\/Penflip\/help\/blob\/master\/writing\/Markdown.txt\n[anaphylaxis]: https:\/\/www.penflip.com\/jeremyvoros\/pv-cards-beta\/blob\/master\/allergyimmunology\/anaphylaxis.txt\n"
      },
      "authors-guide": {
          "slug": "authors-guide",
          "title": "Introduction\n",
          "path": "penflip\/contributor-guide\/authors-guide.txt",
          "markdown": "# Introduction\nWelcome to the Paucis Verbis (PV) cards project! \n\nAs the PV Cards transition from Michelle Lin's side-project of a side-project, it is volunteers like YOU that are going to make it a success and an ongoing valuable resource to the Emergency Medicine (EM) community.\n\nThe goal of this project is to provide a point-of-care resource that is **concise, curated,  and up-to-date**. We want to create content that EM learners, residents, nurses, paramedics and\/or attendings can use in many ways (as a memory-aid, a teaching tool etc.) at the point of care. Knowing which content meets these goals is the art of the project. That is up to you! \n\n## Internet Publishing and the Future of Medical Education\nThis project is designed to disrupt the traditional medical text publishing paradigm. In the current model, content creators create content (textbooks\/journal articles) without being paid and learners read their material (after paying for a book or journal subscription) There are several limitations to this system: \n\n- The publisher is a middleman, operating for profit\n- The peer review and editorial process are slow and non-transparent\n- Key texts are infrequently updated\n- Practice changing literature is hidden behind a paywall\n\nIn this project we are piloting a publishing workflow that is faster, more accessible, more transparent, and free for end users.  \n\n- Content creators will be connected directly with learners.\n- Content is published online enabling new information to be updated and distributed \timmediately. \n- A robust version control system allows all previous versions of the text to be available \tonline, making the editing and peer-review process transparent.\n\n\n## Version Control via Penflip\n**Penflip** is the tool we are using for editing and version tracking. Each contributor has their own version of the PV Cards where they can make changes.  Your version is then submitted to the PV Card editorial staff who review and double check your changes before the master copy is updated. \n\nAll versions of the document are stored in penflip so that no content is ever lost. We even have the ability to roll back previous document states if needed. \n\nCheck out the [Penflip Help] (https:\/\/www.penflip.com\/Penflip\/help) for complete details.\n\n## Markdown\nWe will be using **Markdown** as the editing format for writing the PV Cards. [Markdown] (http:\/\/daringfireball.net\/projects\/markdown\/) is a set of editorial conventions that let you write in plain text which we can easily convert to HTML.  Using the HTML format we can drop the card into a website, mobile app, e-reader book, etc. to make the cards accessible in a multitude of formats.   Essentially Markdown makes your writing internet-portable without being obtrusive. [Nerdplusart has a great editorial on why Markdown is a good choice.] (http:\/\/nerdplusart.com\/markdown-is-the-future\/)\n\nPenflip has a great [cheatsheet on Markdown] (https:\/\/www.penflip.com\/Penflip\/help\/blob\/master\/writing\/Markdown.txt). After browsing that for just a few minutes you will be a Markdown expert. Go on, open up another tab and take a look.\n\nThe next page in this guide will breakdown the components of a PV Card and help you structure your own card using Markdown.\n"
      },
      "jabberwocky": {
          "slug": "jabberwocky",
          "title": "Jabberwocky\n",
          "path": "penflip\/contributor-guide\/jabberwocky.txt",
          "markdown": "# Jabberwocky\n\n**BY LEWIS CARROLL**\n\n![](images\/jabberwocky.jpg)\n\n\u2019Twas brillig, and the slithy toves\n      Did gyre and gimble in the wabe:\nAll mimsy were the borogoves,\n      And the mome raths outgrabe.\n\n\u201cBeware the Jabberwock, my son!\n      The jaws that bite, the claws that catch!\nBeware the Jubjub bird, and shun\n      The frumious Bandersnatch!\u201d\n\nHe took his vorpal sword in hand;\n      Long time the manxome foe he sought\u2014\nSo rested he by the Tumtum tree\n      And stood awhile in thought.\n\nAnd, as in uffish thought he stood,\n      The Jabberwock, with eyes of flame,\nCame whiffling through the tulgey wood,\n      And burbled as it came!\n\nOne, two! One, two! And through and through\n      The vorpal blade went snicker-snack!\nHe left it dead, and with its head\n      He went galumphing back.\n\n\u201cAnd hast thou slain the Jabberwock?\n      Come to my arms, my beamish boy!\nO frabjous day! Callooh! Callay!\u201d\n      He chortled in his joy.\n\n\u2019Twas brillig, and the slithy toves\n      Did gyre and gimble in the wabe:\nAll mimsy were the borogoves,\n      And the mome raths outgrabe.\n\n"
      },
      "abg-interpretation": {
          "slug": "abg-interpretation",
          "title": "Arterial Blood Gas Interpretation\n",
          "path": "penflip\/critical-care\/abg-interpretation.txt",
          "markdown": "# Arterial Blood Gas Interpretation\n\n### Rules of Thumb\n\n1. **Look at pH.** Whichever side of 7.4 the pH is on, the process that caused it to shift to that side is the primary abnormality.\n2. **Calculate the anion gap.** If AG\u226520, there is a primary metabolic acidosis regardless of pH or serum bicarbonate concentration.\n3. **Calculate the excess anion gap** = total anion gap \u2013 12 + measured bicarb. \n\t- If sum is > 30, then metabolic alkalosis.\n\t- If sum is < 23, then nongap metabolic acidosis\n    \n4. **Consider compensation. **\n\t- Respiratory compensation occurs almost immediately in response to metab disorders\n    - Metab compensation occurs over 3-5 days in response to respiratory disorders\n    \n### Primary Respiratory Alkalosis (eg. 7.50 \/ 29 \/ 80 \/ 22)\n- Anxiety\n- Hypoxia\n- Lung disease w\/ or w\/o hypoxia\n- CNS disease\n- Drug use (<span class=\"drug\">ASA<\/span>, <span class=\"drug\">catecholamines<\/span>, <span class=\"drug\">progesterone<\/span>)\n- Pregnancy\n- Sepsis\n- Hepatic encephalopathy \n- Mechanical ventilation\n\n### Primary Respiratory Acidosis\n- e.g. 7.25 \/ 60 \/ 80 \/ 26 = acute b\/c no bicarbonate compensation \n- e.g. 7.34 \/ 60 \/ 80 \/ 31 = chronic b\/c bicarbonate compensation\n\n- CNS depression\n- Neuromuscular disorder\n- Acute airway obstruction\n- Severe pneumonia or pulm edema\n- Impaired lung motion (PTX) \n- Thoracic cage injury \u2013 flail chest \n- Ventilator dysfunction\n\n### Primary Metabolic Alkalosis (eg. 7.50 \/ 48 \/ 80 \/ 36)\n- If Urine Cl is low: Vomiting, NG suction, diuretic use in past, post-hypercapnia\n- If Urine Cl is normal-high: Excess mineralocorticoid activity, current diuretic use,\nexcess alkali administration, refeeding alkalosis\n\n### Primary Metabolic Acidosis (7.20 \/ 21 \/ 80 \/ 8)\n- Nonanion gap: GI bicarb loss (diarrhea, ureteral diversion), renal bicarb loss (RTA,\nearly renal failure, carbonic anhydrase inhibitors, aldosterone inhibitors), HCl\nadministration, post-hypocapnia \n- Anion Gap: MUDPILES\n\n### Pearls\n- If anion gap>20 exists, there is a primary metabolic acidosis.\n- If anion gap exists, calculate the excess anion gap to determine if an underlying\nmetabolic alkalosis or nongap metabolic acidosis exists.\n\n### Examples\n- 7.4 \/ 40 \/ 80 \/ 24, Na 145, Cl 100 --> Metab acidosis + metab alkalosis\n- 7.5 \/ 20 \/ 80 \/ 15, Na 145, Cl 100 --> Resp alkalosis+ metab acidosis+ metab alkalosis \n- 7.1 \/ - 50 \/ 80 \/ 15, Na 145, Cl 100 --> Resp acidosis+ metab acidosis+ metab alkalosis \n- 7.15 \/ 15 \/ 80 \/ 5, Na 140, Cl 110 --> Metab acidosis gap AND nongap\n\n## References\n1. Haber RJ. A practical approach to acid-base disorders. West J Med 1991; 155:146-51.\n\n"
      },
      "rashes-an-approach-to-the-unknown-rash": {
          "slug": "rashes-an-approach-to-the-unknown-rash",
          "title": "Rashes: An approach to the unknown rash\n",
          "path": "penflip\/dermatology\/rashes-an-approach-to-the-unknown-rash.txt",
          "markdown": "# Rashes: An approach to the unknown rash\n##Rash descriptors\n\n**Lesion** Single small diseased area\n**Rash** Eruption of skin, more than single lesion\n___\n**Macule** Circumscribed area of change without elevation\n**Papule** Solid raised lesion < 1 cm\n**Nodule** Solid raised lesion >\/= 1 cm\n**Plaque** Circumscribed elevated confluence of papules >\/= 1 cm\n___\n**Pustule** Circumscribed area containing pus\n**Vesicle** Circumscribed fluid-filled area < 1cm\n**Bulla** Circumscribed fluid-filled area >\/= 1 cm\n___\n**Petichia** Small red\/brown macule >/= 1 cm that does not blanch\n___\n\n|Quick profiling of rash|||\n|:---------------|:-----------------|:----------------------|\n|**Patient age**| 0-5 yrs| Meningococcemia, Kawasaki dz, viral exanthema|\n||65 yrs| Pemphigus vulgaris, sepsis, meningococcemia, TEN, SJS, TSS|\n|**Rash**| Diffuse erythema| Staph SSS, staph\/strep TSS, necrotizing fasciitis|\n||Mucosal lesions| EM, TEN, SJS, pemphigus vulgaris|\n||Petechiae\/purpura|Meningococcemia, necrotizing fasciitis, vasculitis, DIC, RMSF|\n|**Symptom**| Hypotension| Menigococcemia, TSS, RMSF, TEN, SJS|\n\nAbbreviations: \n*TEN: Toxic epidermal necrolysis, SSS: scalded skin syndrome, SJS: Steven-Johnson syndrome, DIC: Disseminated intravascular coagulopathy, TSS: toxic shock syndrome, RMSF: Rocky Mountain spotted feve, EM: Erythema Multiforme major, DRESS: Drug reaction with eosinophilia and systemic symptoms, ITP: Idiopathic thrombocytopenic purpura, TTP: Thrombotic thrombocytopenic purpura*\n\n## Diagnosing: Erythematous Rash\n|||Erythematous rash|||\n|:---:|:---:|:---:|:---:|:----:|\n|||**Nikolsky sign**|||\n||*Yes*||*No*||\n|**Febrile**|**Afebrile**||**Febrile**|**Afebrile**|\n|SSS (pediatric)|SJS\/TEN||TSS|Anaphylaxis|\n|SJS\/TEN(+mucous membranes)|||Kawasaki disease (children, swollen hands, injected sclera)|Scombroid poisoning|\n|DRESS|||Scarlet fever (sand paper rash)|Alcohol flush|\n\n##Diagnosing: Maculopapular Rash\n|||Maculopapular rash|||\n|:--:|:--:|:--:|:--:|:--:|\n||**Central distribution**||**Peripheral distribution**||\n||**Fever\/ill**||**Fever\/ill**||\n|*Yes*|*No*||*Yes*|*No*|\n|Viral exanthum|Drug reaction||Meningococcemia|**Flexor**|\n|Lyme disease|Pityriasis||RMSF, Syphilis|Scabies|\n|DRESS|||Lyme Disease|Eczema|\n||||**(+)Target Lesions**|**Extensor**|\n||||SJS, EM|Psoriasis|\n\n##Diagnosing: Petechial\/Purpuric Rash\n|||Petechial\/purpuric rash|||\n|:--:|:--:|:--:|:--:|:--:|\n||**Febrile\/ill**||**Afebrile**||\n|*Palpable*|*Nonpalpable*||*Palpable*|*Nonpalpable*|\n|Meningococcemia|Purpura fulminans||Autoimmune vasculitis|**Thrombocytopenia**|\n|disseminated gonorrhea|**Thrombocytopenia**|||ITP|\n|endocarditis|DIC||||\n|RMSF|TTP||||\n|Henoch-Schonlein purpura|Dengue||||\n\n##Diagnosing: Vesiculobullous Rash\n|||Vesiculobullous rash|||\n|::--:|:--:|:--:|:--:|:--:|\n||**Febrile**||**Febrile**||\n|*Diffuse distribution*|*Localized distribution*||*Diffuse distribution*|*Localized distribution*|\n|Varicella|Necrotizing faciitis||Pemphigus vulgaris|Burn|\n|Smallpox|Hand-foot-mouth disease||Bullous pemphigoid|Contact dermatitis|\n|Disseminated gonorrhea||||Herpes zoster|\n|Purpura fulminans||||Dyshidrotic ezema|\n|DIC|||||\n\n## Reference:\nMurphy-Lavoie H, LeGros TL.  Emergent Diagnosis of the Unknown Rash. *Emergency Medicine*. 2010 March. (www.emedmag.com)\n\n"
      },
      "dental-infections": {
          "slug": "dental-infections",
          "title": "Dental Infections\n",
          "path": "penflip\/ent\/dental-infections.txt",
          "markdown": "# Dental Infections\n\n**Dental Caries:** demineralization of protective enamel and subsequent tooth decay \n**Pulpitis:** inflammation of pulp secondary to caries\n**Periodontitis:** loss of supportive bone structure caused by chronic gingivitis\n\n![dental-infections.png](images\/dental-infections.png)\n\n### Periapical Abscess\n\n- Collection of purulent material at apex of tooth\n- Secondary to bacterial invasion from carious destruction of enamel\n\ufffc\ufffc\ufffc\ufffc- Hx: Progressive pain, thermal sensitivity\n- P\/E: Caries, decayed tooth, pain w\/ percussion, palpation of apex, gingival swelling, erythema, parulis present, mobile tooth\n- Tx:\n\t1. Antibiotics\n\t\t- Uncomplicated: Penicillin or Clindamycin\n        - Complicated: <span class=\"drug\">Penicillin<\/span> + <span class=\"drug\">Metronidazole<\/span>, <span class=\"drug\">Piperacillin\/Tazobactam<\/span>, or <span class=\"drug\">Clindamycin<\/span> + <span class=\"drug\">Ceftriaxone<\/span> \u2013 40% resistance to \u03b2 lactams in complex odontogenic infections \n\t2. Pain control\n\t3. I+D if abscess present: probe with 18g needle if purulent then 11 blade stab incision hemostat blunt dissection +\/- packing\n\t4. Chlorhexidine 0.1% rinses q2-3h if I + D\n\t5. Surgical referral, if complicated infxn (Ludwig\u2019s, Lemierre\u2019s Syndrome) \n    \n- **Dentist F\/U:** Uncomplicated \u2013 Generalist 1-2 days, Complicated \u2013 Oral Surg ASAP\n   \n### Periodontal Abscess\n- Localized purulent infection within the gingival wall of the periodontal pocket \n- Hx: Swelling, pain, loose tooth\n- P\/E: Purulent discharge, erythema, fluctuant mass, dental extrusion\n- Tx: \n\t1. Pain Control \u2013 dental block, NSAID\u2019s +\/- opioids\n\t2. I + D abscess prn: 11 blade stab incision and hemostat blunt dissection +\/- packing\n\t3. Antibiotics: <span class=\"drug\">Penicillin <\/span>or <span class=\"drug\">Clindamycin<\/span>\n\t4. <span class=\"drug\">Chlorhexidine<\/span> 0.1% rinses q2-3h\n    \n- **Dentist F\/U:** Generalist \u2013 1-2 days\n   \n### Pericoronitis\n- Inflammation +\/- infection surrounding impacted or partially erupted tooth\n\ufffc\ufffc\ufffc\ufffc- Hx: Usually 3rd molar (Wisdom Tooth), erupting teeth, pain, swelling, halitosis \n- P\/E: Erythema, swelling, +\/- abscess\n- Tx: Same as for <b>Periodontal Abscess<\/b>\n- **Dentist F\/U:** Generalist in 1-2 days; definitive treatment \u2013 Oral Surgery\n\n## References\n\n1. DH Nguyen, JT Martin. Am Fam Physician. 2008, 77(6): 797-802.\n"
      },
      "abdominal-pain-diagnostics": {
          "slug": "abdominal-pain-diagnostics",
          "title": "Diagnostic Studies for Acute Abdominal Pain\n",
          "path": "penflip\/general-surgery\/abdominal-pain-diagnostics.txt",
          "markdown": "# Diagnostic Studies for Acute Abdominal Pain\n\n### Imaging\n**Plain abdominal radiography**\n\n-  When compared to unenhanced helical CT, 3-view xrays demonstrated: \n\t- Sensitivity = 30%, Specificity = 88%, Accuracy = 56%\n\t- Negative predictive value = 51%\n- Indications for plain film if suspicious for:\n\t- Pneumoperitoneum (although upright CXR is better)\n\t- Small bowel obstruction (where CT not readily available) \n    - Localization of foreign body ingestion OR catheter \n    \n**CT Abdomen Pelvis**\n\n- Median radiation dose = 15-31 mSv (CXR has 0.1 mSv dose.)\n- Oral contrast likely does NOT provide more information. Known 241-minute delay.\n\n**Ultrasound**\n\n- Increasing use of bedside U\/S for point of care testing in EDs.\n- Advantage: can be used for unstable patients, no radiation exposure\n\n### Diffuse Abdominal Pain\nLactate useful adjunct to risk stratify for mortality. \n\n|Lactate (mmol\/L) |28-day mortality|Death < 3 days|\n|:-----------------:|:---:|:-------------:|\n| < 2.5 | 4.9% | 1.4% |\n| 2.5 - 3.99 | 9.0% | 4.5% |\n| > 4 | 28.4% | 22.4% |\n\n### Diseases\n**Appendicitis:** CT is first-line, unless pediatric or pregnant patient. Then U\/S is first\nline. MRI is an alternative to avoid CT radiation risk.\n\n**Cholecystitis:** Normal LFTs do NOT rule it out. LFT\u2019s helpful as adjunct to\ndetermine likelihood for common bile duct stone.\n\n**Diverticular disease: ** Prevalence < 5% (age < 40 yrs), 30% (age 41-60 yrs), 65%\n(age 61-85 yrs).\n\n**Ectopic pregnancy:** Discriminatory zone for gestational sac is B-HCG \u2265 6,500\n(transabdominal U\/S) or B-HCG \u2265 1,500 (transvaginal U\/S)\n\n**Mesenteric ischemia** of concern because of subtleties in presentation. \n\n- Multidetector CT angiography with reformats: Sens 96%, Spec 94%\n- MR angiography: Sensitivity 85-90% (SMA), 75-90% (celiac artery), 25% (IMA) \u2022 \n\n**Nephrolithiasis:**\n\n- Microscopic hematuria - sens 89%, spec 29%\n- First line imaging: CT \u2013 sens and spec 98-100%\n- If hx of nephrolithiasis, use U\/S (assuming low-risk for alternative dx)\n\n**Pancreatitis:** Lipase (sens 90%, spec 93%) better than Amylase (sens 79%, spec 93%). Unlike level of elevated enzymes, CT correlates with severity.\n\n**UTI:** Urine dipstick alone is adequately predictive, except for children, elderly, suspected urosepsis.\n\n- Nitrites: Odds Ratio = 6.36\n- Leukocyte esterase: OR = 4.52 - Blood: OR = 2.23\n\n**LUQ Pain:** Limited use for labs\/imaging, unless elderly, immunosuppressed, or trauma pt.\n\n## References\n\n1. Panebianco NL, Jahnes K, Mills AM. Emerg Med Clin N Am. 2011;29:175-93.\n2. Shapiro et al. Ann EM 2005\n"
      },
      "infectious-diseases": {
          "slug": "infectious-diseases",
          "title": "ost-Exposure Prophylaxis (PEP): Non-Occupational Contact\n",
          "path": "penflip\/infectious-disease\/infectious-diseases.txt",
          "markdown": "#Post-Exposure Prophylaxis (PEP): Non-Occupational Contact\n\n**Baseline testing of exposed patient:**\n-HIV\n-Hepatitis B (specifically HBsAb for immunity) and Hepatitis C antibody\n-Gonorrhea, chlamydia, syphillis\n-CBC, creatinine, LFT\n-Pregnancy\n\n**Risk of HIV**\n-Receptive anal intercourse: 1-30% risk\n-Insertive anal or receptive vaginal intercourse: 0.1-10% risk\n-Oral intercourse: \"very low risk\" but not zero risk\n-Needle sharing with injection drug use: 0.67% per needle-sharing contact\n\n**HIgh-risk source patient:**\n-Known HIV+ source patient\n-High-risk populations\n\t-Men who have sex with men+\/-women\n    -Commercial sex workers\n    -Injection drug users\n    -History of incarceration\n    -From a country with HIV seroprevalence >1%\n    - Persons with sexual partner in this high-risk population group\n\n**If decide to give PEP for possible HIV exposure:**\n-The sooner the treatment, the better. Start tx less than 48h after exposure. Still eligible if less than 72h.\n- PEP is associated with 81% decrease in HIV transmission.\n- Option #1: <span class=\"drug\">Combivir<\/span> (300mg zidovudine-150mg lamivudine)- 1 tab PO BID\n\t-[nausea, anemia, hepatotoxic, neutropenia, asthenia]\n- Option #2: <span class=\"drug\">Truvada<\/span> (300mg tenofovir-200mg emtricitabine)- 1 tab PO QD\n\t-better tolerated than combivir\n    -[nephrotoxic]\n - For very high-risk exposure: Can add to Option #1 or #2- \n \t- <span class=\"drug\">Kaletra<\/span> (ritonavir-lopinavir), or [hepatotoxic, diarrhea]\n    - <span class=\"drug\">Ritonavir<\/span> **plus** <span class=\"drug\">atazanavir<\/span>, or [hepatotoxic, jaundice, renal stones]\n    - <span class=\"drug\">Ritonavir<\/span> **plus** <span class=\"drug\">darunavir<\/span> [hepatotoxic, diarrhea]\n- Duration of tx = 28 days\n- Followup HIV and syphillis test at 4-6 weeks, 3 months, 6 months post-exposure\n\n**Additional treatment:** (http:\/\/www.cdc.gov\/std\/treatment\/2010\/sexual-assault.htm)\n- <span class=\"drug\">ceftriaxone<\/span> 250mg IM x 1 (for Gonorrhea)\n- <span class=\"drug\">Azithromycin<\/span> 1g PO x1 (for Chlamydia)\n- <span class=\"drug\">Metronidazole<\/span> 2g PO x1 (for trichomonas)\n- Consider emergency contraception for women\n- <span class=\"drug\">Hep B vaccination<\/span> if not fully vaccinated- need to finish series at 1-2 &4-6 mo\n \n\n"
      },
      "strep-pharyngitis": {
          "slug": "strep-pharyngitis",
          "title": "Streptococcal Pharyngitis\n",
          "path": "penflip\/infectious-disease\/strep-pharyngitis.txt",
          "markdown": "# Streptococcal Pharyngitis\n\n- Most cases of pharyngitis are viral\n- Most cases of bacterial pharyngitis are caused by  Group A beta-hemolytic streptococcus\n\t- Incidence 15-30% (children) and 5-20% (adults) Peak season = late winter\/ early spring\n- Transmission is via respiratory secretions\n- Incubation period 24-72 hours\n- Antibiotics shorten symptoms by 16 hours\n\n### Modified Centor Scoring\n\n** Score calculation**\n\n| Criteria\t\t\t\t\t\t\t\t| Points (Total = 5) |\n|------------------------------------|:------------------------:|\n| Absence of cough\t\t\t| 1|\n| Swollen and tender cervical nodes| 1 | \n| Temp > 100.4F (38C) | 1|\n| Tonsillar exudates or swelling | 1 |\n| Patient age: ||\n| - 3-14 yr | 1|\n| - 15-44 yr | 0 |\n| - 45 yr and older | -1 |\n\n** Treatment based on score **\n\n| Modified Centor Score | Incidence of GABHS | Plan |\n|:--------------------------------:|:----------------------------:|--------|\n| 0 | 1-2.5% | No testing, no antibiotics |\n| 1 | 5-10% | No testing, no antibiotics |\n| 2 | 11-17% | Do rapid antigen test |\n| 3 | 28-35% | Do rapid antigen test |\n| \u2265 4| 51-53%  | No testing, empiric antibiotics |\n\n### National Organization Guidelines\n\n1. How to screen for  strep pharyngitis:\n\t- **ACP, CDC, AAFP**: Use Centor criteria to decide testing and antibiotics\n    - **AAP, IDSA**: Use clinical & epidemiological findings to assess risk for GABHS (includes Centor scores)\n2. Diagnostic test\n\t- **ACP, CDC, AAFP**: Rapid antigen test only for Centor scores of 2 or 3 only\n    - **AAP, IDSA**: Rapid antigen test or throat culture for ALL patients at risk\n3. Backup culture needed if rapid antigen test is negative?\n\t- **ACP, CDC, AAFP**: adults - no; children - yes\n    - **AAP**: children - yes\n    - **IDSA**: adults- no; children - yes\n4. Who gets antibiotics?\n\t- **ACP, CDC, AAFP**: Empiric abx for Centor score of \u2265 4, or those with positive rapid antigen test result\n    - **AAP, IDSA**: Positive rapid antigen test or throat culture\n5. Which antibiotic?\n\t- <span class=\"drug\">penicillin V<\/span> oral, <span class=\"drug\">penicillin G benzathine<\/span> IM, or <span class=\"drug\">amoxacillin<\/span> oral\n6. Which antibiotic, if allergic to PCN?\n\t- <span class=\"drug\">erythromycin<\/span>, or first-generation cephalosporin\n\n*ACP = American College of Physicians; CDC = Center for Disease Control; AAFP = American Academy of Family Physicians; AAP = American Academy of Pediatrics; IDSA = ID Society of America*\n---\n\n## References\n- Choby BA. Amer Fam Phys. 2009, 79(5), 383-90.\n"
      },
      "keeping-cards-updated": {
          "slug": "keeping-cards-updated",
          "title": "Stroke: Contraindications for Thrombolytics\n",
          "path": "penflip\/neurology\/keeping-cards-updated.txt",
          "markdown": "# Stroke: Contraindications for Thrombolytics\n\n**Inclusion criteria:**\n___\n*1. Diagnosis of ischemic CVA causing measurable neurologic deficit\n2. Age >\/= 18 years*\n\n|Time Frame|`Exclusion Criteria`|\n|-----------------|:------------------------|\n|**0-3 Hours**| 1.) Significant head trauma or prior stroke in previous 3 months|\n|from| 2.) Symptoms suggest subarachnoid hemorrhage|\n|onset of| 3.) Arterial puncture at noncompressible site in previous  7 days|\n|symptoms|4.) History of previous intracranial hemorrhage|\n|before| 5.) Intracranial neoplasm, AV malformation, or aneurysm|\n|beginning|6.) Recent intracranial or intraspinal surgery|\n|treatment| 7.) Elevated BP (SBP > 185 mmHg or DBP > 110)|\n|| 8.) Active internal bleeding|\n|| 9.) Active bleeding diathesis|\n|| -Platlet count < 100,000\/mm^3 | \n|| -Heparin recieved within 48 hours, resulting in aPTT above upper limit of normal|\n|| -Current use of anticoargulatant with INR > 1.7 or PT > 15 sec|\n|| -Current use of direct thrombin inhibitors or direct factor Xa inhibitors with abnormal sensitive labs tests (aPTT, INR, platlet, ecarin clotting time, TT, factor Xa activity assays)|\n|| 10.) Blood glucose < 50 mg\/dL (2.7 mmol\/L)|\n|| 11.) CT shows multilobar infarct (hypodensity > 1\/3 cerebral hemisphere)|\n|**0-3 hours**| `Relative Exclusion Criteria for IV-tPA`(consider risk-benefit ratio)|\n|| 1.) Only minor or rapidly improving stroke symptoms|\n|| 2.) Pregnancy|\n|| 3.) Seizure at onset with postictal residual neurologic impairments|\n|| 4.) Major surgery or serious trauma within previous 14 days|\n|| 5.) Recent GI or urinary tract hemorrhage within previous 21 days|\n|| 6.) Recent acute MI within presious 3 months|\n|**3-4.5 hours**| `Exclusion Criteria`|\n|| Same exclusion criteria from 0-3 hour time frame above AND any of the following:|\n|| 1.) Age > 80 years|\n|| 2.) Severe stroke (NIHSS > 25)|\n|| 3.) Taking oral anticoagulation regardless of INR|\n|| 4.) History of both diabetes AND prior ischemic stroke|\n\n## References:\n- Jaunch EC et al. Guidlines for early management of patients with acute ischemic stroke (AHA\/ASA). Stroke. 2013; 44(3):870-947.PMD:23370205.\n\n\n\n\n\n\n"
      },
      "vertigo": {
          "slug": "vertigo",
          "title": "Acute Vestibular Syndrome vs Stroke\n",
          "path": "penflip\/neurology\/vertigo.txt",
          "markdown": "# Acute Vestibular Syndrome vs Stroke\n\n**Acute vestibular syndrome (AVS):** Acute dizziness with N\/V, unsteady gait, nystagmus, intolerance to head motion, and lasts \u226524 hrs; no focal neuro signs (hemiparesis, hemisensory loss, gaze palsy)\n\n- Most common causes: Vestibular neuritis (labyrinthitis) and vertebrobasilar CVA \n- Central causes: Vertebrobasilar CVA (83%), multiple sclerosis (11%), other (6%)\n- Over 50% of vertebrobasilar CVA\u2019s have no focal neuro deficit\n- Excludes benign positional vertigo and Meniere\u2019s (< 24 hrs of continuous sx)\n\n**Which *bedside* tests can help differentiate peripheral from central causes of AVS?**\n\n### NOT HELPFUL\n\n- Differentiating type of dizziness (vertigo, presyncope, unsteadiness)\n- Onset of dizziness (sudden vs gradual)\n- Provocative head movement (eg. Hallpike-Dix)\n- Proportionality of sx such as severity of dizziness, vomiting, gait impairment (eg. severe gait impairment with mild dizziness does not mean central cause)\n- Hearing loss\n- Patterns and vectors of nystagmus\n- Noncontrast head CT has sensitivity of only 16% for acute ischemic CVA\n\n### HELPFUL\n\n- **Multiple prodromal episodes of dizziness** \u2013 Predictive of central cause (CVA)\n- **Headache or neck pain** \u2013 Predictive of central cause (CVA, vertebral artery dissection) with positive LR = 3.2. Absence of pain not as predictive.\n- **Any neurologic signs, esp. truncal ataxia** (unable sit upright with arms crossed) and severe gait instability \u2013 Strongly predictive of central cause\n- **Horizontal head impulse test** (vestibular-ocular reflex) \u2013 If normal, predictive of central cause (positive LR 18.4, negative LR 0.16)\n- **Gaze-evoked nystagmus** (right-beating nystagmus on right gaze and left-beating nystagmus on left gaze) = dysfunction of gaze-holding structures in brainstem and cerebellum \u2013 If abnormal, predictive of central cause (specificity 92%, sens 38%)\n- **Vertical ocular misalignment on alternate cover test** \u2013 If abnormal skew deviation, predictive of central cause (specificity 98%, sens 30%)\n- **Diffusion-weighted MRI** is good but not perfect - Sensitivity 83% for ischemic CVA\n\n### H.I.N.T.S. EXAM\n\n- **H**ead **I**mpulse test\n- Gaze-evoked **N**ystagmus\n- **T**est of **S**kew\n\nAbnormal findings summarized using INFARCTs acronym:\n\n- **I**mpulse **N**ormal\n- **F**ast-phase **A**lternating\n- **R**efixation on **C**over **T**est\n\nIf any 1 of 3 abnormal, sensitivity 100% and specificity 96% for central cause\n\nHINTS test seems just as good as diffusion-weighted MRI to r\/o CVA in AVS.\n\n---\n\n## References\n\n- Tarnutzer AA et al. CMAJ. 2011; 183(9): E571-592.\n- Kattah et al, Stroke, 2009\n\n\n\n\n\n\n\n"
      },
      "orthopedics": {
          "slug": "orthopedics",
          "title": "C1 and C2 Fractures\n",
          "path": "penflip\/orthopedics\/orthopedics.txt",
          "markdown": "# C1 and C2 Fractures\n\n|Injury (mechanism)|Stable|Comment|\n|-----------------|:---:|:-------------|\n|**Atlanto-occipital dislocation (flexion)**|No|Often instantly fatal, more common in children because of small horizontally-oriented occipital condyles, dislocation can be anterior (most common), superiorly distracted, or posterior|\n\n\n"
      },
      "pain-medications": {
          "slug": "pain-medications",
          "title": "Initial ED Pain Medication Options in Adults\n",
          "path": "penflip\/pharmacology\/pain-medications.txt",
          "markdown": "# Initial ED Pain Medication Options in Adults\n\n### Pain Medication\n| Acetaminophen \t\t|\t\t\t\t\t\t\t\t\t\t \t\t\t\t\t\t|\n|-------------------------------|-------------------------------------------------- |\n| Acetaminophen \t\t| 500-1000 mg PO\t\t\t\t\t\t\t\t|\n|\t\t\t\t\t\t\t\t\t\t|1000 mg IV over 15 minutes\t\t\t   |\n|\t\t\t\t\t\t\t\t\t\t| 650 mg PR\t\t\t\t\t\t\t\t\t\t\t |\n\n| NSAIDS\t\t\t\t\t\t|\t\t\t\t\t\t\t\t\t\t \t\t\t\t\t\t|\n|-------------------------------|-------------------------------------------------- |\n| Ibuprofen\t\t\t\t\t   | 400-600 mg PO\t\t\t\t\t\t\t\t\t|\n| Naproxen \t\t\t\t\t  | 250-500 mg PO\t\t\t\t\t\t\t\t   |\n| Ketorolac\t\t\t\t\t\t| 10 mg PO\t\t\t\t\t\t\t\t\t\t\t  |\n|\t\t\t\t\t\t\t\t\t\t| 10-15 mg IV\t\t\t\t\t\t\t\t\t\t |\n| Indomethacin\t\t\t   | 25-50 mg PO\t\t\t\t\t\t\t\t\t  |\n\n\n| Non-Opioids\t\t\t\t|\t\t\t\t\t\t\t\t\t\t \t\t\t\t\t\t|\n|-------------------------------|-------------------------------------------------- |\n| Lidocaine 1%\t\t\t\t| Local\/regional anesthetic: \t\t\t\t|\n|\t\t\t\t\t\t\t\t\t\t| (Max: 4 mg\/kg; 7 mg\/kg with epi)   |\n| \t\t\t\t\t\t\t\t\t\t| 5-20 mL intra-articular\t\t\t\t\t  |\n| Lidocaine 2%\t\t\t\t| Local\/regional anesthetic: \t\t\t\t|\n| \t\t\t\t\t\t\t\t\t\t| (Max: 4 mg\/kg; 7 mg\/kg with epi)\t  |\n|\t\t\t\t\t\t\t\t\t\t| 1.5 mg\/kg IV cardiac lidocaine in 100 mL NS over 10 min  (Max: 4 mg\/kg over 60 minutes) |\n|\t\t\t\t\t\t\t\t\t\t | Continuous infusion: 1.5-2.5 mg\/kg\/hr IV (Max for 24 hr) |\n|  Lidoderm 5% patch   | Apply on skin\t\t\t\t\t\t\t\t\t\t|\n| Bupivacaine 0.25-0.5% | Local\/regional anesthetic: \t\t\t  |\n|\t\t\t\t\t\t\t\t\t\t | Max dose: 2.5 mg\/kg; 3 mg\/kg with epi |\n| Triamcinolone \t\t\t | 2.5-40 mg intra-articular\t\t\t\t  |\n| Gabapentin\t\t\t\t   | 100-300 mg PO\t\t\t\t\t\t\t\t    |\n| Pregabalin\t\t\t\t\t | 25 mg PO\t\t\t\t\t\t\t\t\t\t\t   |\n| Ketamine *Subdissociative dose* |\t0.3 mg\/kg IV in 100 mL NS over 10 min |\n|\t\t\t\t\t\t\t\t\t\t\t| Continuous infusion: 0.15 mg\/kg\/hr IV (100 mg in 100 mL NS)  |\n|\t\t\t\t\t\t\t\t\t\t\t| 1  mg\/kg IN (no more than 1 mL per nostril) |\n\n| Opioids\t\t \t\t\t\t\t\t\t\t\t\t\t\t |\t\t\t\t\t\t\t\t\t\t \t\t\t\t\t\t|\n|----------------------------------------------------------|-------------------------------------------------- |\n| Oxycodone (5 mg tablet) \t\t\t\t\t\t   | 1-2 tabs PO\t\t\t\t\t\t\t\t\t      |\n| Hydrocodone (5 mg tablet)\t\t\t\t\t\t | 1-2 tabs PO\t\t\t\t\t\t\t\t\t\t    |\n| Oxycodone\/acetaminophen (5\/325 mg tablet)\t\t| 1-2 tabs PO\t\t\t\t  \t\t   |\t\n| Hydrocodone\/acetaminophen (5\/325 mg tablet)  | 1-2 tabs P \t\t\t\t\t\t   |\n| Hydrocodone\/ibuprofen  (2.5\/200 mg tablet)\t\t| 1-2 tabs PO\t   \t\t\t\t\t  |\n| Hydromorphone\t\t\t\t\t\t\t\t\t\t\t| Weight-based: 0.015 mg\/kg IV titrate Q 15 min |\n|\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t | Fixed dose: 1 mg IV titrate Q 10-15 min \t\t|\n|\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t | 2-4 mg IM\t\t\t\t\t\t\t\t\t\t\t|\n|\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t| 2-4 mg PO\t\t\t\t\t\t\t\t\t\t\t\t|\n| Morphine\t\t\t\t\t\t\t\t\t\t\t\t\t\t| Weight-based: 0.1 mg\/kg IV titrate Q 20 min |\n|\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t  | Fixed dose: 5 mg IV titrate Q 10-15 min  |\n| \t\t\t\t\t|Fixed dose infusion: 10 mg IV in 100 mL NS over  10 min titrate Q 20-30 min |\n|\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t| 10-20 mg nebulized with 3 mL NS\n| Fentanyl \t\t\t\t\t\t\t\t\t|Weight-based: 1-1.5 mcg\/kg IV in 100 mL NS over 5-10 min  |\n|\t\t\t\t\t\t\t\t\t\t\t\t\t| Fixed dose: 50-100 mcg IV in 100 mL NS over 10 min   |\n|\t\t\t\t\t\t\t\t\t\t\t\t\t| 1-2 mcg\/kg IN (no more than 1 mL per nostril) |\n| \t\t\t\t\t\t\t\t\t\t\t\t\t| 2-4 mcg\/kg nebulized |\n| Naloxone \t\t\t\t\t\t\t\t\t| (for opioid-induced pruritus)\t0.25-0.5 mcg\/kg\/hr IV (2 mg naloxone in 100 mL NS)  |\n\n\n### Pain Syndromes\n\n| Abdominal Pain (non-traumatic)\t\t\t |\t\t\t\t\t\t\t\t\t\t \t\t\t\t\t\t|\n|----------------------------------------------------------|-------------------------------------------------- |\n| Ketorolac \t\t\t\t\t\t\t\t\t\t\t\t\t | 10-15 mg IV\t\t\t\t\t\t\t\t\t\t\t|\n| Rescue Opioids \t\t\t\t\t\t\t\t\t\t\t| Morphine\/Fentanyl IV (weight-based or fixed) |\n\n| Abdominal Pain (traumatic)\t\t\t \t\t  |\t\t\t\t\t\t\t\t\t\t \t\t\t\t\t\t|\n|----------------------------------------------------------|-------------------------------------------------- |\n| Opioids \t\t\t\t\t\t\t\t\t\t\t\t\t\t  | Morphine\/Fentanyl IV (weight-based or fixed) |\n| Acetaminophen \t\t\t\t\t\t\t\t\t\t  | 1 g IV over 15 min (adjunct to opioids) |\n\n| Back Pain (acute) \t|\t\t\t\t\t\t\t\t\t\t\t\t| \n|-----------------------------|---------------------------------------|\n| NSAID\t\t\t\t\t\t\t| Ibuprofen or naproxen\t\t|\n| Methocarbamol \t  | 1500 mg PO\t\t\t\t\t\t   |\n| Diazepam\t\t\t\t\t| 5 mg PO\t\t\t\t\t\t\t\t|\n\n| Back Pain (chronic)\t|\t\t\t\t\t\t\t\t\t\t\t\t|\n|-------------------------------|-------------------------------------|\n| Gabapentin \t\t\t\t| 100-300 mg PO\t\t\t\t\t |\n| Pregabalin \t\t\t\t   | 25 mg PO\t\t\t\t\t\t\t|\n| Lidoderm 5% Patch\t  |\tNo more than 4 patches in 24 hr |\n\n| Dental Pain\t\t\t\t|\t\t\t\t\t\t\t\t\t\t\t\t| \n|-----------------------------|---------------------------------------|\n| NSAID\t\t\t\t\t\t\t| Ibuprofen or naproxen\t\t|\n| Dental Blocks\t\t\t   | 5 mL of Lidocaine (1-2%)   \u2013OR\u2013  \n2 mL of Bupivacaine (0.25-0.5%) |\n\n| Headache \t\t\t\t   |\t\t\t\t\t\t\t\t\t\t\t\t| \n|-----------------------------|---------------------------------------|\n| **Oral**\t\t\t\t\t |\t\t\t\t\t\t\t\t\t\t\t\t|\n| NSAID\t\t\t\t\t\t\t| Ibuprofen or naproxen\t\t|\n| Butalbital\/ acetaminophen\/caffeine (50\/325\/40 mg)\t| 1-2 tabs PO\t|\n| Metoclopramide\t\t| 10 mg PO \t\t\t\t\t\t\t |\n|**Parenteral (in order of preference)** |\t\t\t|\n| Metoclopramide\t\t| 10 mg IV (Slow drip over 10-15 min) |\n| Diphenhydramine \t\t| 25-50 mg IV\t\t\t\t\t\t|\n| Prochlorperazine \t\t\t| 10 mg IV\t\t\t\t\t\t\t|\n| Chlorpromazine\t\t\t| 0.1 mg\/kg IV\t\t\t\t\t\t|\n| Sumatriptan\t\t\t\t\t| 6 mg SQ, repeat with 12 mg SQ (after 1 h) |\n| Dihydroergotamine\t\t  | 0.25 mg IV, repeat with 1 mg (after 1 h) |\n| Valproate\t\t\t\t\t\t\t| 300-1000 mg IV (over 30 min) |\n| Magnesium\t\t\t\t\t\t| 2 gm IV (30-60 min)\t\t\t|\n| Droperidol \t\t\t\t\t\t| 1-2.5 mg IV\t\t\t\t\t\t\t|\n|\t\t\t\t\t\t\t\t\t\t\t| 2.5-8 mg IM \t\t\t\t\t\t\t|\n| Haloperidol \t\t\t\t\t\t| 2.5-5 mg IV\t\t\t\t\t\t\t|\n|**Regional Nerve Blocks** |\t\t\t\t\t\t\t\t\t\t|\n| Paracervical block\t\t\t| 5 mL of Lidocaine (1-2%)   \u2013OR\u2013  2-3 mL of Bupivacaine (0.25-0.5%) |\n| Occipital nerve block\t\t\t| 5 mL of Lidocaine (1-2%)   \u2013OR\u2013  2-3 mL of Bupivacaine (0.25-0.5%) |\n\n|Musculoskeletal Pain (non-traumatic)\t  |\t\t\t\t\t\t\t\t\t\t \t\t\t\t\t\t|\n|----------------------------------------------------------|-------------------------------------------------- |\n| NSAID\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t  | Ibuprofen, naproxen, or indomethacin |\n| Local\/Regional Blocks \t\t\t\t\t\t\t\t| Lidocaine or bupivacaine \u00b1 epinephrine |\n\n| Neuropathic Pain   |\t\t\t\t\t\t\t\t\t\t\t\t| \n|-----------------------------|---------------------------------------|\n| Gabapentin \t\t\t| 100 mg PO\t\t\t\t\t\t\t\t|\n| Pregabalin\t\t\t\t| 25 mg PO\t\t\t\t\t\t\t\t|\n| Lidocaine 2%\t\t\t| Loading dose and infusion IV |\n\n| Renal Colic \t\t\t    |\t\t\t\t\t\t\t\t\t\t\t\t| \n|-----------------------------|---------------------------------------|\n| Ketorolac\t\t\t\t\t | 10-15 mg IV\t\t\t\t\t\t\t|\n| Rescue Opioids \t\t| Morphine\/Fentanyl IV (weight-based or fixed) |\n| Lidocaine 2% \t\t\t | Loading dose and infusion |\n\n|Sickle Cell Pain Crisis\t    |\t\t\t\t\t\t\t\t\t\t\t\t| \n|------------------------------------|---------------------------------------|\n| **Intravenous (IV)**\t\t|\t\t\t\t\t\t\t\t\t\t\t\t|\n| Opioids \t\t\t\t\t\t\t\t| Morphine, fentanyl, or hydromorphone (weight based or fixed dosing) |\n| Ketamine *subdissociative dose*\t| 0.3 mg\/kg IV in 100 mL NS over 10 min \t|\n|\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t| 0.15-0.25 mg\/kg\/hr IV continuous infusion |\n| **Subcutaneous (SQ)** |\t\t\t\t\t\t\t\t\t\t\t\t|\n| Morphine \t\t\t\t\t\t\t| 0.1 mg\/kg or 5 mg SQ fixed dose with titration q 10-15 min |\n| Hydromorphone\t\t\t\t| 1-1.5 mg SQ with titration Q 15 min |\n| Ketamine *subdissociative dose* |\t0.3 mg\/kg SQ over 10 min |\n| **Intranasal (IN)**\t\t\t|\t\t\t\t\t\t\t\t\t\t\t\t|\n| Fentanyl \t\t\t\t\t\t\t\t| 1-2 mcg\/kg IN titrate Q 5-10 min |\n| Ketamine *subdissociative dose* | 1 mg\/kg IN titrate Q 5-10 min |\n| **Nebulized** \t\t\t\t\t|\t\t\t\t\t\t\t\t\t\t\t\t|\n| Fentanyl \t\t\t\t\t\t\t\t\t| 2-4 mcg\/kg nebulized single dose   |\n| **Intramuscular (IM) route is _DISCOURAGED!_** |\t\t|\n\n\n|Trauma & Burns\t\t\t\t  |\t\t\t\t\t\t\t\t\t\t\t\t\t| \n|------------------------------------|---------------------------------------|\n| Local\/Regional Blocks\t\t| Lidocaine or bupivacaine \u00b1 epinephrine |\n| Opioids\t\t\t\t\t\t\t\t| Morphine\/Fentanyl (weight-based or fixed) |\n| Ketorolac\t\t\t\t\t\t\t  | 10-15 mg IV\t\t\t\t\t\t\t\t|\n| Acetaminophen \t\t\t   | 1 g IV over 15 min (adjunct to opioids\/ NSAIDS\/ketamine) |\n\n| Opiate-Tolerant Patient or Refractory\/Intractable Pain |\n|-------------------------------------------------------------------|\n| Consider subdissociative dosing of ketamine. |\n\n\n\n\n\n"
      }
  }
}
